Introduction: Vraylar (cariprazine) was first approved by the FDA in 2015 to treat schizophrenia and bipolar disorder (Stewart, 2022). Subsequently, it received FDA approval for maintenance treatment of schizophrenia (APA, 2019), treatment of bipolar depression, and, most recently, as an adjunctive treatment for major depressive disorder. The National Institute of Mental Health (NIMH) estimates that in 2020, 21 million adults in the United States, or approximately 8.4 % of al
